Literature DB >> 11433225

Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis.

G P Visentin1, M Moghaddam, S E Beery, J G McFarland, R H Aster.   

Abstract

Heparin-induced thrombocytopenia (HIT), with or without thrombosis, is a common and often serious complication of heparin therapy. Platelet-activating, heparin-induced antibodies characteristic of HIT are thought to be specific for complexes formed between platelet factor 4 (PF4) and heparin, and such complexes are routinely used for antibody detection. We studied the binding of HIT antibodies to PF4 complexed with heparin fractions of uniform molecular size or linear polyanions other than heparin and found that many compounds other than heparin form complexes with PF4 that are suitable for antibody detection, provided they carry strong negative charges spaced about 0.5 nm apart along the molecular backbone and are of sufficient length to span about 40% of the circumference of the PF4 tetramer. Polyvinyl phosphonate was among the compounds that were equivalent to heparin. Thus neither a polysaccharide chain nor sulfate side groups--the hallmarks of heparin structure--are required for HIT antibody detection. The findings support the view that antibodies associated with HIT are specific for conformational changes that take place in the positively charged PF4 molecule when it reacts with a suitable, linear polyanion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11433225     DOI: 10.1067/mlc.2001.115525

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  28 in total

1.  Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia.

Authors:  Janice McFarland; Andrew Lochowicz; Richard Aster; Bryan Chappell; Brian Curtis
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

2.  A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis.

Authors:  Anand Padmanabhan; Curtis G Jones; Brian R Curtis; Daniel W Bougie; Mia J Sullivan; Namrata Peswani; Janice G McFarland; Daniel Eastwood; Demin Wang; Richard H Aster
Journal:  Chest       Date:  2016-02-19       Impact factor: 9.410

3.  Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.

Authors:  Lubica Rauova; Li Zhai; M Anna Kowalska; Gowthami M Arepally; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

4.  Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients.

Authors:  Vanessa Nellen; Irmela Sulzer; Gabriela Barizzi; Bernhard Lämmle; Lorenzo Alberio
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

5.  High sensitivity and specificity of an automated IgG-specific chemiluminescence immunoassay for diagnosis of HIT.

Authors:  Theodore E Warkentin; Jo-Ann I Sheppard; Lori-Ann Linkins; Donald M Arnold; Ishac Nazy
Journal:  Blood       Date:  2018-07-31       Impact factor: 22.113

6.  Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis.

Authors:  Anand Padmanabhan; Curtis G Jones; Daniel W Bougie; Brian R Curtis; Janice G McFarland; Demin Wang; Richard H Aster
Journal:  Blood       Date:  2014-10-23       Impact factor: 22.113

7.  B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia.

Authors:  Yongwei Zheng; Alexander W Wang; Mei Yu; Anand Padmanabhan; Benjamin E Tourdot; Debra K Newman; Gilbert C White; Richard H Aster; Renren Wen; Demin Wang
Journal:  Blood       Date:  2013-12-19       Impact factor: 22.113

8.  Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

Authors:  Theodore E Warkentin; Richard J Cook; Victor J Marder; Jo-Ann I Sheppard; Jane C Moore; Bengt I Eriksson; Andreas Greinacher; John G Kelton
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

9.  Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery.

Authors:  Seiji Bito; Shigeki Miyata; Kiyoshi Migita; Mashio Nakamura; Kazuhito Shinohara; Tomotaro Sato; Takeharu Tonai; Motoyuki Shimizu; Yasuhiro Shibata; Kazuhiko Kishi; Chikara Kubota; Shinnosuke Nakahara; Toshihito Mori; Kazuo Ikeda; Shusuke Ota; Takeshi Minamizaki; Shigeru Yamada; Naofumi Shiota; Masataka Kamei; Satoru Motokawa
Journal:  Blood       Date:  2015-12-09       Impact factor: 22.113

10.  Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4.

Authors:  Miriam E Jaax; Krystin Krauel; Thomas Marschall; Sven Brandt; Julia Gansler; Birgitt Fürll; Bettina Appel; Silvia Fischer; Stephan Block; Christiane A Helm; Sabine Müller; Klaus T Preissner; Andreas Greinacher
Journal:  Blood       Date:  2013-05-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.